Olatoyosi Odenike to Interleukin-3 Receptor alpha Subunit
This is a "connection" page, showing publications Olatoyosi Odenike has written about Interleukin-3 Receptor alpha Subunit.
Connection Strength
0.060
-
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
Score: 0.060
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.